Evaluation of analgesic activity of sodium valproate and ethanolic extract of *Vitex negundo* in experimental analgesic models in wistar rats

Ravi K. Sori¹, Basavaraj Poojar², Nandan Hodlur³, Amod Tilak², Rupa Korde¹, Priya Gandigawad¹*

¹Department of Pharmacology, SDM College of Medical Sciences and Hospital, Dharwad, Karnataka, India
²Department of Pharmacology, Kasturba Medical College Mangalore (Manipal University), Karnataka, India
³Department of Dravyaguna, BVVS Ayurvedic Medical College and Hospital, Bagalkot, Karnataka, India

Received: 10 August 2018  
Accepted: 31 August 2018

*Correspondence to:*
Dr. Priya Gandigawad,  
Email: soriravi@gmail.com

ABSTRACT

**Background:** NSAIDs and opioids are commonly prescribed medications to relieve pain of multiple aetiologies with no effect on the level of consciousness of the patient. They interfere with the mode of transmission of the pain message. A widely prescribed antiepileptic drug, sodium valproate has been used in various non-epileptic conditions like migraine prophylaxis and in the treatment of bipolar disorder because of the multiple mechanisms by which it acts. *Vitex negundo* has been investigated for antipyretic, analgesic, anti-inflammatory, anticonvulsant, hepatoprotective and bronchial relaxant. Very few studies have been done to evaluate its analgesic activity and no study was done on analgesic activity with the combination of modern drug. The more important point to be noted is that *Vitex negundo* is a natural product and therefore unlikely to cause adverse effects when compared to the traditional drugs used to treat pain. The aim of the present study was to evaluate of analgesic activity of sodium valproate and docosahexaenoic in experimental analgesic models in wistar rats.

**Methods:** For analgesic activity, a total of 36 adult Wistar albino rats were taken and divided into six groups of six rats each. Group I was control (distil water 1ml/kg), Group II received intraperitoneal injection of diclofenac sodium (10mg/kg). Group III, IV were injected intraperitoneal sodium valproate 200, 400mg/kg with distil water respectively and Group V, VI were given sodium valproate 200, 400mg/kg (intraperitoneal) plus EEVN 400mg/kg (orally) respectively. Analgesic activity was assessed using hot plate, tail flick and acetic acid writhing models.

**Results:** Present study revealed that sodium valproate at higher doses (400mg/kg) used either alone along with EEVN (400mg/kg) showed statistically significant analgesic activity in comparison to control in various experimental models for assessing pain.

**Conclusions:** Combination of sodium valproate along with EEVN has shown promising analgesic activity.

**Keywords:** Analgesia, Antiepileptic, Acetic acid writhing, Hot plate, Tail flick

INTRODUCTION

Pain has been defined by the international association for the study of pain (1979) as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage.”¹⁰ Pain is an unpleasant sensation localized to a part of body. It is often described in terms of a penetrating or tissue-destructive process (twisting, stabbing tearing, squeezing and burning) and/or of a bodily or emotional reaction (terrifying, nauseating, and sickening). Furthermore, any pain of moderate or high intensity is accompanied by
anxiety and an urge to escape or terminate the feeling. These symptoms depict the dual nature of pain: it is both sensation and emotion. When acute, pain is characteristically associated with behavioural arousal and a stress response consisting of increased blood pressure, heart rate, pupil diameter and plasma cortisol levels. Pain is a pervasive public health problem, and analgesic drugs play a central role in its treatment. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are currently the most widely prescribed drugs for the treatment of pain and inflammation. They are more effective in controlling painful inflammatory conditions like osteoarthritis, ankylosing spondylitis, rheumatoid arthritis etc. However, there are number of side effects associated with the use of NSAIDs. The traditional NSAIDs usually cause gastrointestinal adverse effects on long term use and the selective cyclooxygenase (COX2) inhibitors are known to possess dangerous cardio toxic potential. The other group of drugs used in the management of pain is opioid analgesics which are having the good pain-relieving activity. However, in patients with chronic pain opioids are rather avoided due to its addiction liability and abuse potential.

Researchers have been continuously exploring newer molecules to develop an ideal analgesic which is non-toxic as well as effective at the same time. A widely prescribed antiepileptic drug, sodium valproate has been used in various non-epileptic conditions like migraine prophylaxis and in the treatment of bipolar disorder because of the multiple mechanisms by which it acts. Sodium valproate is an inhibitor of Histone Deacetylation (HDAC). Rat stroke models in the past have demonstrated the neuroprotective effect of valproate due to HDAC inhibition.

**Vitex negundo** Linn (Family: Verbenaceae) is a woody, aromatic shrub growing to a small tree. Some common names are in Hindi nirgundi and in Sanskrit as sindhuvara. All parts of the plant from root to fruit possess a multitude of phytochemical secondary metabolites which impart an unprecedented variety of medicinal uses to the plant. **Vitex negundo** has been investigated for antipyretic, analgesic, anti-inflammatory, anticonvulsant, hepatoprotective and bronchial relaxant. Very few studies have been done to evaluate its analgesic activity and no study was done on analgesic activity with the combination of modern drug. The more important point to be noted is that **Vitex negundo** is a natural product and therefore unlikely to cause adverse effects when compared to the traditional drugs used to treat pain.

From the view of various existing reports, authors initiated a study to evaluate the analgesic activity of sodium valproate and ethanolic extract of **Vitex negundo** in experimental analgesic models in wistar rats.

**METHODS**

An in vivo experimental study conducted after taking the approval from the institutional animal ethics committee.

**Chemicals**

Three drugs were used during the study; diclofenac sodium (Cipla), sodium valproate (Zydus Pharmaceuticals) and ethanolic extract of **Vitex negundo** (EENV) were used. The pure powder form of sodium valproate was used, dissolved in distilled water. Acetic acid used for writhing test.

**Equipment’s**

Feeding tube, Eddy’s hot plate, tail flick analgesiometer were used, Soxhlet apparatus.

**Plant preparation and extraction**

The fresh leaves were purchased from the local market and the leaves of **Vitex negundo** were shade dried and coarsely powdered. The powder is filled in to filter paper bag and placed in the soxhlet apparatus for extraction. The soxhlet apparatus is connected to round bottom flask which is fill by ethanol (90%) solvent and water bath to maintain temperature. The ethanol was boiled at 40°C for over a period of 24hours. The extract obtained was 20% and was stored in desiccator at room temperature.

**Selection of the animal**

Thirty-six male albino Wistar healthy rats were taken from the central animal house for the study. The animals weighed 150g to 200g and the animals were housed under standard condition, housed individually with normal water and food granules, 12:12 hours light dark cycle, 50% humidity and 28°C temperature and provided with standard food granules and water ad libitum. These animals were individually housed in poly propylene cages which contained paddy husk (procured locally) which was sterile.

**Identification of individual animals**

Rats from each treatment group were marked using different coloured marks on their tails, for easy identification and experimentation, according to the group allotted.

**Sample size**

The minimum number of rats in each group was kept as six, so as to obtain statistically significant results within and between the groups.

**Evaluation of analgesic activity**

A total of 36 adult Wistar albino rats were divided into six groups. Each group contained six rats. They were weighed and marked. Group I was control (distilled water 1ml/kg), Group II received intraperitoneal injection of diclofenac sodium (10mg/kg), Group III, IV were injected intraperitoneal sodium valproate 200, 400mg/kg dissolved with distilled water and Group VI, VII, were given sodium...
valproate 200, 400mg/kg dissolved with distilled water along with EEVN 400mg/kg (orally) respectively. The dose of sodium valproate was chosen as 200mg/kg and 400mg/kg based on a study performed by Raza M et al. The dose of EEVN was chosen as 400mg/kg based on a study done by Maniyar YA et al.

The albino Wistar rats were weighed and marked. The test drugs were injected according to the group and after 30 minutes of post administration of test drug, 2% acetic acid was injected intraperitoneally in order to produce writhing. Ten minutes post administration of 2% acetic acid writhing movements like elongation of body, abdominal constriction, trunk twisting, forelimb extension, hind limb extension and back arching were counted cumulatively for a period of 20 minutes.

**Statistical analysis**

The results will be analysed using one way ANOVA followed by post-hoc Tukey’s test in SPSS 21 Software for Microsoft. The statistically significant value for any measure was set to p < 0.05 at a confidence interval of 95%. The results expressed is in mean±standard deviation.

**RESULTS**

**Hot plate method**

The pain reaction was significantly increased with the standard group diclofenac sodium 10mg/kg to 11.34±0.38, 13.44±0.32 and 16.02±0.41 at 60, 90 and 120th minute respectively when compared to control group 4.8±0.36. The pain reaction in group 4 sodium valproate 400mg/kg was also significantly increased to 10.48±0.22, 12.09±0.60, 14.00±0.18 at 60, 90 and 120th minute respectively when compared to control group 4.8±0.36.

There is also significance increase in reaction time seen with group 5 the sodium valproate 200mg/kg plus EEVN 400 mg/kg when compared to control group 11.06±0.41, 11.48±0.22, 12.08±0.33 at 60, 90, 120th minute. Group 6 sodium valproate 400mg/kg plus EEVN 400mg/kg shown high significance with control group when compared to other groups 12.08±0.44, 13.58±0.62, and 14.28±0.52 at 60, 90 and 120th minute (Table 2).

**Tail flick method**

The tail flick time or withdrawal response was significantly increased to 8.7±0.30 in the diclofenac sodium 10mg/kg treated group, 7.56±0.40 in the sodium valproate 400mg/kg group and 8.16±0.35 in the sodium valproate 400mg/kg plus EEVN 400mg/kg group at 90 minutes when compared to control.

The tail flick time or withdrawal response was significantly increased to 9.35±0.18 (p < 0.001) in the diclofenac sodium 10 mg/kg treated group, 8.58±0.42 in the sodium valproate 400mg/kg group and 9.37±0.23 in the sodium valproate 400mg/kg plus EEVN 400mg/kg at 120 minutes when compared to control 5.15±0.31 (Table 3).
Table 2: Eddy’s hot plate method - retention time at different time points (in seconds).

| Groups                        | 0 min | 15 min | 30 min | 60 min | 90 min | 120 min |
|-------------------------------|-------|--------|--------|--------|--------|---------|
| Control                       | 3.52±0.21 | 3.51±0.26 | 4.82±0.36 | 4.19±0.17 | 3.27±0.39 | 3.48±0.21 |
| Standard-diclofenac sodium    | 6.35±0.59 | 6.93±0.58 | 9.28±0.29 | 11.34±0.38 | 13.44±0.32 | 16.02±0.4 |
| Sodium valproate 200mg/kg     | 5.72±0.86 | 5.98±0.44 | 6.01±0.28 | 6.18±0.22 | 6.24±0.73 | 6.44±0.39 |
| Sodium valproate 400mg/kg     | 5.88±1.38 | 6.43±2.86 | 7.04±0.56 | 10.48±0.22 | 12.09±0.60 | 14.00±0.18 |
| Sodium valproate 200mg/kg EEVN | 4.13±0.19 | 6.28±1.16 | 7.33±1.02 | 11.06±0.41 | 11.48±0.22 | 12.08±0.33 |
| Sodium valproate 400mg/kg + EEVN | 6.04±0.48 | 7.08±0.22 | 7.48±0.33 | 12.08±0.44 | 13.58±0.62 | 14.28±0.52 |

All values are expressed as Mean±SEM; a denotes p<0.05 compared to baseline; b denotes p<0.05 compared to control; and c denotes p<0.05 compared to standard; p-value obtained by one-way ANOVA followed by Post-Hoc Tukeys test.

Table 3: Tail flick method-retention time at different time points (in seconds).

| Groups                        | 0 min | 15 min | 30 min | 60 min | 90 min | 120 min |
|-------------------------------|-------|--------|--------|--------|--------|---------|
| Control                       | 4.58±0.2 | 5.08±0.23 | 5.27±0.12 | 5.20±0.48 | 5.28±0.21 | 5.15±0.31 |
| Standard-diclofenac Sodium    | 3.58±0.14 | 4.47±0.22 | 5.54±0.32 | 6.58±0.18 | 8.7±0.3 | 9.35±0.18 |
| Sodium valproate 200mg/kg     | 5.62±0.76 | 5.88±0.24 | 6.21±0.28 | 6.30±0.12 | 6.34±0.53 | 6.54±0.38 |
| Sodium valproate 400mg/kg     | 6.08±1.88 | 6.33±2.86 | 7.24±0.56 | 10.18±0.12 | 7.56±0.40 | 8.58±0.42 |
| Sodium valproate 200mg/kg + EEVN | 4.23±0.19 | 6.48±1.16 | 7.43±1.02 | 10.06±0.41 | 11.48±0.22 | 12.08±0.33 |
| Sodium valproate 400mg/kg + EEVN | 6.44±0.38 | 7.28±0.21 | 7.58±0.33 | 12.58±0.24 | 8.16±0.35 | 9.37±0.23 |

All values are expressed as Mean ±SEM; a denotes p<0.05 compared to baseline; b denotes p<0.05 compared to control; and c denotes p<0.05 compared to standard; p-value obtained by one-way ANOVA followed by Post-Hoc Tukeys test.

Writhing test method

The number of abdominal constrictions or writhing were significantly reduced to 5.48±0.58 in the diclofenac sodium 10mg/kg treated group, 21.63±2.81 in the sodium valproate 200mg/kg group, 7.58±1.66 in the sodium valproate 400mg/kg group, 18.14±1.02 in the sodium valproate 200mg/kg plus EEVN 400mg/kg group and 6.07±1.28 in the sodium valproate 400mg/kg plus EEVN 400mg/kg group when compared to control 36.5±4.8 (Table 4).

Table 4: Writhing test response.

| Groups                        | Writhing response |
|-------------------------------|-------------------|
| Control                       | 34.5±4.4          |
| Standard - Diclofenac Sodium  | 5.48±0.58         |
| Sodium Valproate 200mg/kg     | 21.63±2.81        |
| Sodium Valproate 400mg/kg     | 7.58±1.66         |
| Sodium Valproate 200mg/kg + EEVN | 18.14±1.02      |
| Sodium Valproate 400mg/kg + EEVN | 6.57±1.28       |

All values are expressed as Mean±SEM; b denotes p<0.05 compared to control; and c denotes p<0.05 compared to standard p-value obtained by one-way ANOVA followed by Post-Hoc Tukey’s test.

DISCUSSION

NSAIDs and opioids are commonly prescribed medications to relieve pain of multiple aetiologies with no effect on the level of consciousness of the patient. They interfere with the mode of transmission of the pain message.

The present study was carried out using different experimental pain models to evaluate analgesic activity of sodium valproate and EEVN. The analgesic models in our experiment was checked using Eddy’s hot plate, tail flick and acetic acid writhing models which are standard models for screening agents for analgesic activity.

In the hot plate model sodium valproate 400mg/kg, sodium valproate 200mg with 400mg of EEVN and sodium valproate 400mg with 400mg EEVN showed significant analgesic activity compared to control group at 60 minutes, 90minutes and 120minutes. In the tail flick model, sodium valproate given at 400mg and sodium valproate 400mg with 400mg of EEVN showed significant analgesic activity when compared to control at 90 and 120minutes. In the acetic acid Writhing model, sodium valproate given at a dose of 200mg, sodium valproate given at a dose of 400mg, sodium valproate 200mg with 400mg of EEVN and sodium valproate 400mg with 400mg of EEVN showed significant analgesic activity as compared to control. It has been reported that sodium valproate possessed analgesic activity.

International Journal of Basic & Clinical Pharmacology | October 2018 | Vol 7 | Issue 10 | Page 2039
when used alone.17 Similarly Nakamoto K et al, reported that EEVN when used alone possessed analgesic activity Manirujjaman et al, but the co-administration of EEVN along with sodium valproate has potentiated the analgesic activity of the latter.18

The analgesic activity of sodium valproate can be attributed to the increase in glutamate transporters like glial Glutamate Transporter 1 (GLT 1) and Glutamate Aspartate Transporter (GLAST), in dorsal horn of the spinal cord and also in the hippocampus. This action of sodium valproate is due to inhibition of histone deacetylation.19 Medsjian et al, attributes the analgesic activity of sodium valproate to its effect on GABA neurotransmission. Sodium valproate is said to increase the GABA neurotransmission causing analgesia.20

Similar to sodium valproate, Similarly Vitex negundo possesses analgesic activity via central mechanisms involving these receptor systems or via peripheral mechanisms involved in the inhibition of prostaglandins, leukotrienes and other endogenous substances that are key mediators in pain. Previous studies suggested that alkaloids also involve in analgesic action through non-narcotic action.21-24 In the present study, flavonoids, tannins and alkaloids might be attributed to the peripheral and central analgesic activities. This may be the probable reason for potentiating the analgesic activity of sodium valproate by EEVN.

Limitations of this study were a single dose of EEVN has been selected in last two groups. The dose dependent effects were not known. Mechanisms mentioned in previous studies were considered instead. The mechanisms by which sodium valproate and EEVN showed analgesic activity was not studied.

CONCLUSION

In conclusion, the combination of sodium valproate and EEVN has shown promising analgesic activity and was almost comparable to standard drugs used in this study. However, no clear inference can be drawn at this stage and hence we consider the work for further extensive research.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Negus SS, Vanderah TW, Brandt MR, Bilsky EJ, Becerra L, Borsook D. Preclinical assessment of candidate analgesic drugs: recent advances and future challenges. J Pharmacol Experimental Therapeut. 2006 Nov 1;319(2):507-14.
2. Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacological Rev. 2001 Dec 1;53(4):597-652.
3. Bhalerao PP, Pawade RB, Joshi S. Evaluation of analgesic activity of Dashamoola formulation by using experimental models of pain. Indian J Basic Appl Med Res. 2015;4(3):245-55.
4. Kunder SK, Bairy LK. Arivazhahan A. Effect of sodium valproate and docosahexaenoic acid on pain in rats. J Clin Diagnostic Res. 2017 Mar;11(3):FF05.
5. DeVane CL. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull. 2003;37:25-42.
6. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmcol Experimental Therapeut. 2007 Jun 1;321(3):892-901.
7. Tirumalasetty J, Ubedulla S, Chandrasekhar N, Kishan PV, Rasamal K. Evaluation of antipyretic activity of alcoholic extract of Vitex negundo leaves in PGE1 induced pyrexia model in Albino rats. J Chem Pharm Res. 2012;4(6):3015-9.
8. Telang RS, Chatterjee S, Varshneya C. Studies on analgesic and anti-inflammatory activities of Vitex negundo Linn. Indian J Pharmocol. 1999;31:363-6.
9. Upalendu J, Chattopadhyay RN, Badri PS. Preliminary studies on anti-inflammatory activity of Zingiber officinale Rosc., Vitex negundo Linn and Tinospora cordifolia (willd) Miers in albino rats. Indian J Pharmocol. 1999 May 1;31(3):232.
10. Ravishankar B, Bhaskaran NR, Sasikala CK. Pharmacological evaluation of Vitex negundo (Nirgundi) leaves. Bull Med Ethno Bot Res. 1985;6(1):72-92.
11. Gupta M, Mazumder UK, Bhawal SR. CNS activity of Vitex negundo Linn in mice. Indian J Exp Biol. 1999;37:143-6.
12. Percival M. Understanding the natural management of pain and inflammation. Clin Nutr Insights. 1999;4(30):1-5.
13. Raza M, Dharriwal MA, Ageel AM, Qureshi S. Evaluation of the anti-inflammatory activity of sodium valproate in rats and mice. Gen PharmacoL. 1996;27(8):1395-400.
14. Maniyar YA, Sriraj D. Evaluation of anti-inflammatory activity of ethanolic extract of vitex negundo flowers in experimental animals. Indian J Pharma PharmacoL. 2017;4(4):172-5.
15. Gao J, Wang X, Sun H, Cao Y, Lian S, Wang H, et al. Neuroprotective effects of docosahexaenoic acid on hippocampal cell death and learning and memory impairments in a valproic acid-induced rat autism model. Int J Developmental Neurosci. 2016 Apr 1;49:67-78.
16. Richette P, Bardin T, Gout. Lancet. 2010;375:318-28.
17. Jaiswal SR, Sontakke SD. Experimental evaluation of analgesic and anti-inflammatory activity of simvastatin and atorvastatin. Indian J PharmacoL. 2012;44(4):475-79.
18. Manirujjaman, Sultana F, Md. Haque IU, Md. Chowdhury R, Md. Hossain T. In vivo assay of
analgesic activity of methanolic and petroleum ether extracts of *Vitex negundo* leaves. J Pharma Biol Sci. 2013;7(3):56-9.

19. Witkin LB, Heubner CF, Galdi F, O'keefe E, Spitaletta P. Plummer AJ. Pharmacology of 2-amino-indane hydrochloride (Su-8629): a potent non-narcotic analgesic. J Pharmacol Exp Therapeut. 1961 Sep 1;133(3):400-8.

20. Mesdjian E, DeFeudis FV, Valli M, Jadot G, Mandel P. Antinociceptive action of sodium valproate in the mouse. Gen Pharmacol. 1983;14(6):697-99.

21. Koster R, Anderson M, de Beer EJ. Acetic acid for analgesic screening. Fed Proc. 1959;18:138.

22. Taber RI, Greenhouse DD, Rendell JK, Irwin S. Agonist and antagonist interactions of opioids on acetic acid-induced abdominal stretching in mice. J Pharmacol Exp Ther. 1969;169(1):29-38.

23. Schumacher GA, Goodell H, Hardy JD, Wolff HG. Uniformity of the pain threshold in man. Science. 1940 Aug 2;92(2379):110-2.

24. Wolff HG, Hardy JD, Goodell H. Studies on pain. Measurement of the effect of morphine, codeine, and other opiates on the pain threshold and an analysis of their relation to the pain experience. J Clin Investigation. 1940 Jul 1;19(4):659-80.

Cite this article as: Sori RK, Poojar B, Hodlur N, Tilak A, Korde R, Gandigawad P. Evaluation of analgesic activity of sodium valproate and ethanolic extract of *Vitex negundo* in experimental analgesic models in wistar rats. Int J Basic Clin Pharmacol 2018;7:2036-41.